Condition: Myelodysplastic Syndromes · Sponsor: Institute of Hematology & Blood Diseases Hospital, China
This study aims to evaluate whether immediate allogeneic hematopoietic stem cell transplantation (HSCT) is non-inferior to HSCT following bridging therapy in patients with higher-risk myelodysplastic syndrome (HR-MDS).
This description comes directly from the study's public registry record.
Jiang Erlie, doctor · +86-15122538106 · jiangerlie@ihcams.ac.cn
Xiao Zhijian, doctor · +86-13821085716 · xiaozhijian@ihcams.ac.cn
Always discuss trial participation with your own doctor first.
| Peking University People's Hospital | Beijin, Beijing Municipality, China | Recruiting |
| Zhengzhou University First Affiliated Hospital | Zhengzhou, Henan, China | Recruiting |
| The 960th Hospital of the Joint Service Support Force of the Chinese People's Liberation Army | Jinan, Shandong, China | Recruiting |
| People's Liberation Army The General Hospital of Western Theater Command | Chengdu, Sichuan, China | Recruiting |
| The Second Hospital of Hebei Medical University | Shijia Zhuang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06918834